* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Jagdeep Bachher
Chief Investment Officer
Oakland, California
4/23/2020
*Owl Rock Capital Corporation and RAPT Therapeutics Inc. were inadvertently left off the previously filed 13F filings. **Oncternal Therapeutics Inc was inadvertently left off the previously filed 13F filings. Additionally, the share amount is based on a estimate of the June 2019 pre-merger shares of 1,459,524 shares multiplied by the merger exchange ratio of 0.073386, which equals to 107,108 shares. This amount was then multiplied by the share price as of March 31, 2020, which was $2.93, leading to the market value of about $314,000.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.